Meet Your Team
Carol W. Lustig, RN, ANP-BC, ACGN, is a Nurse Practitioner with expertise in cancer genetic risk assessment and cancer screening and prevention. She is the Assistant Clinical Director of the Hereditary Cancer Program and a certified Advanced Clinical Genomic Nurse.
Ashley L. Hendershot, DNP, FNP-BC, is a Doctorate-prepared Nurse Practitioner with clinical expertise in hereditary cancer syndromes, breast cancer screening and risk reduction, and women’s health. In addition to her clinical role, she leads quality improvement initiatives in the Hereditary Cancer Program.
Meghan L. Underhill-Blazey PhD, APRN, is a Nurse Practitioner with expertise in cancer genetics and prevention. In addition to clinical practice, she is faculty at the University of Rochester School of Nursing and leads research to on how to help individuals understand and live with inherited cancer risk.
Laura Kent, RN, BSN, OCN, has been a nurse for more than 38 years with experience in cardio thoracic surgery, obstetrics, occupational medicine, and oncology. She has been at the Wilmot Cancer Center for eight years working in lymphoma, gastrointestinal, genitourinary and soft tissue cancer clinics. She joined the Hereditary Cancer Program in November 2019.
Who else is on the team?
This multidisciplinary team approach is unique to this program. For each inherited cancer syndrome, there are many organs that can be affected. We utilize the experts at the University of Rochester Medical Center to screen for cancer early and often. Early detection is key to the best outcome.
After your personalized cancer screening plan is made, we will refer you to cancer screening specialists who have an expertise in hereditary cancer syndromes. For example, if you need to have colonoscopies routinely, we can arrange for you to be seen by a gastroenterologist who specializes in colon screening for those who carry an increased risk of developing cancer because of an inherited genetic syndrome.
Cancer screening recommendations are made based on national comprehensive cancer guidelines, as well as the consensus of a multidisciplinary conference which meets monthly.